Bassil I. Dahiyat Ph.D.
Net Worth
Last updated:
What is Bassil I. Dahiyat Ph.D. net worth?
The estimated net worth of Dr. Bassil I. Dahiyat Ph.D. is at least $16,403,396 as of 22 Nov 2024. He owns shares worth $2,729,240 as insider, has earned $3,954,856 from insider trading and has received compensation worth at least $9,719,300 in Xencor, Inc..
What is the salary of Bassil I. Dahiyat Ph.D.?
Dr. Bassil I. Dahiyat Ph.D. salary is $971,930 per year as Co-Founder, Chief Executive Officer, Pres & Director in Xencor, Inc..
How old is Bassil I. Dahiyat Ph.D.?
Dr. Bassil I. Dahiyat Ph.D. is 55 years old, born in 1970.
What stocks does Bassil I. Dahiyat Ph.D. currently own?
As insider, Dr. Bassil I. Dahiyat Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Xencor, Inc. (XNCR) | Co-Founder, Chief Executive Officer, Pres & Director | 352,615 | $7.74 | $2,729,240 |
What does Xencor, Inc. do?
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
Bassil I. Dahiyat Ph.D. insider trading
Xencor, Inc.
Dr. Bassil I. Dahiyat Ph.D. has made 17 insider trades between 2015-2024, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 249,914 units of XNCR stock on 12 Mar 2015. As of 22 Nov 2024 he still owns at least 352,615 units of XNCR stock.
Xencor key executives
Xencor, Inc. executives and other stock owners filed with the SEC:
- Dr. Allen S. Yang M.D., Ph.D. (57) Senior Vice President & Chief Medical Officer
- Dr. Bassil I. Dahiyat Ph.D. (55) Co-Founder, Chief Executive Officer, Pres & Director
- Dr. John R. Desjarlais (61) Senior Vice President of Research & Chief Scientific Officer
- Mr. John J. Kuch (66) Senior Vice President & Chief Financial Officer
- Ms. Celia E. Eckert J.D. (53) Vice President, Gen. Counsel & Corporation Sec.